ESTRO 2022 - Abstract Book

S483

Abstract book

ESTRO 2022

Conclusion This is the first large retrospective study to report patient-level analysis of N+PCa prostate cancer. We have shown that definitive treatment with ADT and prostate RT is associated with improved survival. Our follow-on work aims to build a prognostic model and validate our findings with an independent data set.

MO-0556 Treating oligometastatic prostate cancer – a survey among the German Society for Radiation Oncology

P. Rogowski 1 , C. Trapp 1 , R. von Bestenbostel 1 , D. Konnerth 1 , S. Marschner 1 , N. Schmidt Hegemann 1 , C. Belka 1,2 , M. Li 1

1 University Hospital, LMU Munich, Department of Radiation Oncology, Munich, Germany; 2 German Cancer Consortium (DKTK), German Cancer Consortium (DKTK), Munich, Germany Purpose or Objective Due to improved imaging, oligometastatic prostate cancer (OMPC) is diagnosed more frequently. Growing evidenceshows that patients with a limited number of metastases benefit from primary-directed (PDT) as well as from metastasis-directed radiotherapy (MDT). The purpose of this survey was to investigate the current treatment practice for OMPC among German radiation oncologists.

Materials and Methods

Members of the German Society for Radiation Oncology (DEGRO) were surveyed via an anonymous online questionnaire sent

by e-mail. The survey included six general items and 14 specific items regarding treatment characteristics. Questionnaires

with at least 50 percent of questions completed were considered for further analysis.

Results A total of 204 responses were received (15% response rate). 167 were considered for further analysis. Most respondents stated to be specialized in treating prostate cancer patients and to treat 10-30 patients with OMPC per annum. 97% considered PSMA-PET/CT necessary to define oligometastatic disease. Opinions differed regarding the use of systemic therapies: 63% of the respondents aimed to defer systemic therapy using radiotherapy in OMPC, 37% considered systemic therapy as necessary. In the setting of synchronous OMPC, 97% recommended PDT with or without a combination of MDT and/or systemic therapy. For metachronous nodal or bone oligometastatic recurrence, 98% and 99%, respectively, would opt for MDT. The majority would combine MDT with systemic therapy in patients with metachronous oligorecurrence. Respondents recommended normofractionation, hypofractionation and SBRT for lymph node metastases in 49%, 27% and 24%, respectively. No consensus existed regarding the field size for MDT of lymph node metastases. Most respondents preferred > 5 fractions for treatment of bone metastases.